Merck's (MRK -2.9%) Tredaptive (Cordaptive) cholesterol treatment failed to meet its primary...
Thursday, December 20, 2012, 9:00 AM ETMerck's (MRK -2.9%) Tredaptive (Cordaptive) cholesterol treatment failed to meet its primary goal in a massive study of 25,673 patients. The drug didn't significantly cut the risk of coronary deaths, non-fatal heart attacks, strokes or revascularizations compared with statin therapy. Merck will end its bid to for regulatory approval of Tredaptive in the U.S.; the drug is sold in 40 countries and had sales of $13M in Q1-Q3. (PR)
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles